APG Asset Management N.V. raised its position in Johnson & Johnson (NYSE:JNJ) by 48.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,027,056 shares of the company’s stock after buying an additional 2,291,900 shares during the period. Johnson & Johnson accounts for 1.5% of APG Asset Management N.V.’s investment portfolio, making the stock its 3rd biggest holding. APG Asset Management N.V. owned 0.26% of Johnson & Johnson worth $913,588,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Harding Loevner LP purchased a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in shares of Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. increased its stake in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares during the last quarter. Mountain Capital Investment Advisors Inc purchased a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $124,000. Finally, Shine Investment Advisory Services Inc. purchased a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $177,000. Hedge funds and other institutional investors own 65.70% of the company’s stock.
JNJ has been the subject of several research analyst reports. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Royal Bank of Canada raised their price objective on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, October 18th. Vetr downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $146.35 price objective for the company. in a report on Friday, December 22nd. Citigroup started coverage on shares of Johnson & Johnson in a report on Monday, September 25th. They issued a “neutral” rating and a $140.00 price objective for the company. Finally, Goldman Sachs Group downgraded shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and raised their price objective for the stock from $125.00 to $130.00 in a report on Wednesday, September 20th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $145.47.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company posted $1.68 EPS. sell-side analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.39%. The ex-dividend date was Monday, November 27th. Johnson & Johnson’s payout ratio is presently 58.33%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.